(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Nations for Setting up camp - 2From Amateur to Master: My Involvement in Photography
- 3The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- 4Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- 5A Manual for Pick Great Lawful Discussion Administrations For New businesses In 2024
- 6 US States for Fly Fishing
- The most effective method to Shake Hands During a Pandemic: Wellbeing Tips and Behavior
- Vote In favor of Your #1 Cell phones
- Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts.
- Go on A Careful spending plan: Modest Objections for Your List of must-dos
- German finance minister sees advantages of smartphones in schools
- Discovering a true sense of harmony: Contemplation and Care Practices
- The Solution to Flexibility: Developing Internal Fortitude Notwithstanding Misfortune
- The Best Internet based Courses for Expertise Improvement
